246 related articles for article (PubMed ID: 32265819)
1. Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions.
Alharbi M; Mobark N; Bashawri Y; Abu Safieh L; Alowayn A; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; AlSolme E; Ahmad M; Al-Banyan A; Alotabi FE; Serrano J; Snuderl M; Al-Rashed M; Abedalthagafi M
Front Neurol; 2020; 11():167. PubMed ID: 32265819
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
[TBL] [Abstract][Full Text] [Related]
3. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
4. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia.
Rajagopal R; Teng AJ; Jawin V; Wong OL; Mahsin H; Abd Rani NH; Yap TY; Gunasagaran K; Thevarajah A; Yeoh SL; Ong GB; Ariffin H; Jones D; Bouffet E; Gottardo NG
Front Oncol; 2023; 13():1278611. PubMed ID: 37920166
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
7. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of Tumor-Infiltrating B Cells in Group 4 Medulloblastoma in Children.
Wu KS; Jian TY; Sung SY; Hsieh CL; Huang MH; Fang CL; Wong TT; Lin YL
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563678
[TBL] [Abstract][Full Text] [Related]
9. Molecular Classification of Medulloblastoma.
Kijima N; Kanemura Y
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
[TBL] [Abstract][Full Text] [Related]
10. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
12. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
13. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors.
Moss RM; Sorajja N; Mills LJ; Moertel CL; Hoang TT; Spector LG; Largaespada DA; Williams LA
Front Oncol; 2023; 13():1113121. PubMed ID: 37035203
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Drivers in Pediatric Medulloblastoma.
Roussel MF; Stripay JL
Cerebellum; 2018 Feb; 17(1):28-36. PubMed ID: 29178021
[TBL] [Abstract][Full Text] [Related]
18. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
[TBL] [Abstract][Full Text] [Related]
19. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
20. Singular Value Decomposition-Based Penalized Multinomial Regression for Classifying Imbalanced Medulloblastoma Subgroups Using Methylation Data.
Mohammed I; Elbashir MK; Faggad AS
J Comput Biol; 2024 May; 31(5):458-471. PubMed ID: 38752890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
